Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A new dry eye treatment is turning heads. TTAX03, a powdered amniotic membrane derived from placenta and umbilical cord tissue, significantly reduced dry eye symptoms in a phase 2 randomized trial with no serious adverse events. The highest dose group saw the biggest improvements in both corneal staining and symptom scores, with benefits lasting through day 85.
A new dry eye treatment is turning heads. TTAX03, an investigational lyophilized (freeze-dried) powdered amniotic membrane developed by BioTissue, showed meaningful improvements in dry eye disease signs and symptoms in a phase 2 randomized controlled trial. Presented at the American Academy of Ophthalmology annual meeting, the study enrolled 73 adults with mild to moderate dry eye disease and superficial punctate keratopathy.
Unlike conventional amniotic membrane treatments — which can blur vision during wear due to their semitranslucent nature — TTAX03 was designed for easier delivery and better tolerability. Participants wore a bandage contact lens with or without TTAX03 for 5 days across four dosage groups, with follow-up assessments through day 85.
By the Numbers:
Why it matters: Dry eye disease affects millions globally and current treatments often require daily use. TTAX03's single-application design with durable effects could offer a more convenient, patient-friendly alternative — if larger trials confirm these early findings.